Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
Though hepatic resection and ablation are the curative treatments for patients with hepatocellular carcinoma (HCC), the 5-years recurrence-free survival is lower than 30%. In recent years, several immune checkpoint inhibitors have been approved in advanced or unresectable HCC. No study about the safety and efficacy of adjuvant immune checkpoint inhibitors for patients with HCC after hepatectomy is reported.
Epistemonikos ID: 3a10c71b76a2eaffd71e21e9c569be7e006a225f
First added on: Feb 19, 2024